CO-DIAGNOSTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 USD | -4.39% |
|
-1.80% | -18.05% |
| May. 13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
| May. 09 | Transcript : Co-Diagnostics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 5.82M | Sales 2025 * | - | Capitalization | 34.07M |
|---|---|---|---|---|---|
| Net income 2024 * | -31M | Net income 2025 * | - | EV / Sales 2024 * | 5.85 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.1
x | P/E ratio 2025 * |
-
| Employees | 155 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Co-Diagnostics, Inc.
More recommendations
More press releases
| 1 day | -4.39% | ||
| 1 week | -1.80% | ||
| Current month | -6.03% | ||
| 1 month | -5.22% | ||
| 3 months | -6.03% | ||
| 6 months | -21.01% | ||
| Current year | -18.05% |
1 week
1.08
1.19
1 month
1.031.30
Current year
1.021.50
1 year
0.981.89
3 years
0.9811.82
5 years
0.6930.99
10 years
0.6930.99
| Managers | Title | Age | Since |
|---|---|---|---|
Dwight Egan
CEO | Chief Executive Officer | 70 | 13-04-17 |
Brian Brown
DFI | Director of Finance/CFO | 48 | 21-02-21 |
Mark Poritz
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Reed L. Benson
LAW | General Counsel | 77 | 14-10-31 |
Richard Serbin
BRD | Director/Board Member | 79 | 17-04-30 |
Dwight Egan
CEO | Chief Executive Officer | 70 | 13-04-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 28 M€ | -0.48% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 1.09 | -4.39% | 58,800 |
| 24-05-16 | 1.14 | +1.79% | 41,906 |
| 24-05-15 | 1.12 | 0.00% | 28,385 |
| 24-05-14 | 1.12 | +4.19% | 69,847 |
| 24-05-13 | 1.075 | -3.15% | 41,381 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.09
USD
Average target price
2.5
USD
Spread / Average Target
+129.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.05% | 34.07M | |
| -19.42% | 18.12B | |
| -41.90% | 2.87B | |
| +19.36% | 1.9B | |
| -1.05% | 1.65B | |
| +33.96% | 1.34B | |
| -16.83% | 957M | |
| -21.96% | 896M | |
| +7.07% | 841M | |
| +10.85% | 523M |
- Stock Market
- Equities
- CODX Stock
